Login to Your Account



AACR 2014

Palbociclib shows PFS but not (yet?) OS benefit in phase II

By Anette Breindl
Science Editor

Tuesday, April 8, 2014
SAN DIEGO – Results presented at the of the American Association for Cancer Research (AACR) annual meeting on Sunday from the phase II PALOMA-1 trial of CDK inhibitor palbociclib (Pfizer Inc.) led to plenty of buzz that Pfizer Inc. might file for accelerated approval for the drug, despite the lack of an overall survival (OS) benefit to date.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription